Syndax Total Current Assets from 2010 to 2025

SNDX Stock  USD 13.08  0.08  0.62%   
Syndax Pharmaceuticals Total Current Assets yearly trend continues to be fairly stable with very little volatility. Total Current Assets are likely to outpace its year average in 2025. Total Current Assets is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. View All Fundamentals
 
Total Current Assets  
First Reported
2012-12-31
Previous Quarter
446.1 M
Current Value
414.8 M
Quarterly Volatility
165.4 M
 
Yuan Drop
 
Covid
Check Syndax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syndax Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.1 K, Interest Expense of 227.2 K or Selling General Administrative of 65.6 M, as well as many indicators such as Price To Sales Ratio of 6.97, Dividend Yield of 0.0198 or PTB Ratio of 2.59. Syndax financial statements analysis is a perfect complement when working with Syndax Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Syndax Pharmaceuticals Correlation against competitors.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Latest Syndax Pharmaceuticals' Total Current Assets Growth Pattern

Below is the plot of the Total Current Assets of Syndax Pharmaceuticals over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Syndax Pharmaceuticals' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syndax Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Current Assets10 Years Trend
Slightly volatile
   Total Current Assets   
       Timeline  

Syndax Total Current Assets Regression Statistics

Arithmetic Mean230,228,198
Geometric Mean55,604,304
Coefficient Of Variation112.04
Mean Deviation224,681,623
Median108,510,000
Standard Deviation257,949,591
Sample Variance66538T
Range700.7M
R-Value0.91
Mean Square Error11699.6T
R-Squared0.84
Slope49,535,357
Total Sum of Squares998069.9T

Syndax Total Current Assets History

2025701.4 M
2024668 M
2023580.9 M
2022481.3 M
2021448.4 M
2020298.9 M
201962.3 M

About Syndax Pharmaceuticals Financial Statements

Syndax Pharmaceuticals investors use historical fundamental indicators, such as Syndax Pharmaceuticals' Total Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Syndax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Current Assets668 M701.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.